ClinicalTrials.gg
CompletedNCT04700618Updated Feb 16, 2022

A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old

A Phase 4 interventional study of 23-valent pneumococcal polysaccharide vaccine in Vaccination, sponsored by China National Biotec Group Company Limited. Completed at 1 site in China. Open to participants aged 60 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-16.

Sponsored by China National Biotec Group Company Limited (part of Sinopharm) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
330
Allocation
Non-randomized
Ages
60 Years to 70 Years
Sex
All
01

Study summary

Objective: To evaluate the safety and immunogenicity of PPV23 vaccine revaccinated in 60-70 years old in Shanghai.

Read the detailed description
  1. Antibody double growth rate in 28-40 days after immunization;
  2. Antibody GMC level in 28-40days after immunization;
  3. Incidence of adverse reactions in 0-30days.
02

Conditions studied

  • Vaccination

Keywords

  • safety
  • immunogenicity
03

In context

Lead sponsor

China National Biotec Group Company Limited is the lead sponsor of 37 studies on the registry; 2 are open to participants now.

First submitted after China National Biotec Group Company Limited became part of Sinopharm.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The age was 60-70 years old on the day of enrollment;
  2. The subjects have signed the and signed the date;
  3. The subjects are able to participate in all planned follow-up visits and were able to follow all trial procedures (e.g. complete diary card / contact card, return to visit);
  4. The subjects in the study group had been vaccinated with 23 valent pneumococcal polysaccharide vaccine made in China for more than 5 years;
  5. The control group had never been vaccinated with any pneumococcal vaccine; 6.Axillary temperature ≤37.0℃.

Exclusion criteria

Exclusion Criteria:

  1. With a medical history with hypersensitiveness, eclampsia, epilepsy, cerebropathia and neurological illness;
  2. Allergic to any ingredient of vaccine or with allergy history to any vaccine; 3.Subjects with immunodeficency or suspected impairment of immunologic function (e.g. caused by ), or subjects are in the process of immunosuppressor therapy(Taking orally injecting of hormone);

4.Administration of immunoglobulins within 30 days prior to this study; 5.Acute febrile disease(temperature ≥ 37.0°C) or infectious disease; 6.With a clearly diagnosed history of thrombocytopenia or other coagulopathy, may cause for subcutaneous injection; 7.With any serious chronic illness, acute infectious diseases, or respiratory diseases; 8.Suffering from serious cardiovascular diseases (pulmonary heart disease, pulmonary edema, hypertension can not be controlled to normal by drugs), liver and kidney diseases, diabetes with complications; 9.With any kind of infectious, purulent, or allergic skin diseases; 10.With any other factor that makes the investigator determines the subject is unsuitable for this study.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    Study group

    The subjects in the study group had been vaccinated with 23 valent pneumococcal polysaccharide vaccine made in China for more than 5 years.

    Biological: 23-valent pneumococcal polysaccharide vaccine

  • Placebo comparator
    Control group

    The control group had never been vaccinated with any pneumococcal vaccine.

    Biological: 23-valent pneumococcal polysaccharide vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Antibody doubling rate

    The difference of serum antibody double growth level between the two groups was compared.

    Time frame: The blood collection time was 28-40 days after vaccination.

Secondary outcomes

  1. Antibody GMC level

    The difference of serum antibody GMC level between the two groups was compared.

    Time frame: The blood collection time was 28-40 days after vaccination.

  2. Incidence of adverse reactions

    Adverse reactions were collected during the observation period.

    Time frame: Within 30 days after vaccination.

07

Study locations

1 site
  • Shanghai municipal center for disease control and prevention
    Shanghai, Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Aug 2021, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2021
First posted
Jan 8, 2021
StartActual
Mar 21, 2021
Primary completionActual
Aug 22, 2021
CompletionActual
Feb 13, 2022
Last update
Feb 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04700618
Collaborators
Shanghai Municipal Center for Disease Control and Prevention
Responsible party
Sponsor
First posted
Jan 8, 2021
Start date
Mar 21, 2021
Primary completion
Aug 22, 2021
Completion
Feb 13, 2022
Last update
Feb 16, 2022

Study contacts

Xiang Guo
study chair · Shanghai Municipal Center for Disease Control and Prevention

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine

Start the discussion